Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 69Multiple Myeloma 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Myelodysplastic Syndromes 37Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Non-Hodgkin 33Leukemia 32Recurrence 31Lymphoma, B-Cell 30Melanoma 27Lymphoma, Large B-Cell, Diffuse 22Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hematologic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Burkitt Lymphoma 16Neoplasms 15Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Carcinoma, Renal Cell 12Head and Neck Neoplasms 11Neuroblastoma 10Leukemia, Biphenotypic, Acute 10Graft vs Host Disease 10Neoplasms, Plasma Cell 9Neoplasm Metastasis 9Colorectal Neoplasms 9Breast Neoplasms 9

Interventions

tetulomab tetraxetan lu-177 2osimertinib 2fludarabine 2entinostat 2Pemetrexed 2Lutetium 2Carboplatin 2spartalizumab 1pembrolizumab 1nirogacestat 1interferon gamma-1b 1gilteritinib 1ficlatuzumab 1emvododstat 1denileukin diftitox 1atezolizumab 1Trabectedin 1Taxes 1Sunitinib 1Radiosurgery 1Oncolytic Virotherapy 1Nivolumab 1Lutetium-177 1Interleukin-2 1Interferon-gamma 1Immunotherapy 1Idarubicin 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Histologic Type × fludarabine × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

University Health Network, Toronto

Phase 1 Recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡